IN2012DN00407A - - Google Patents
Info
- Publication number
- IN2012DN00407A IN2012DN00407A IN407DEN2012A IN2012DN00407A IN 2012DN00407 A IN2012DN00407 A IN 2012DN00407A IN 407DEN2012 A IN407DEN2012 A IN 407DEN2012A IN 2012DN00407 A IN2012DN00407 A IN 2012DN00407A
- Authority
- IN
- India
- Prior art keywords
- lipocalin mutein
- lipocalin
- conjugates
- formulations
- administration
- Prior art date
Links
- 102000019298 Lipocalin Human genes 0.000 abstract 7
- 108050006654 Lipocalin Proteins 0.000 abstract 7
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 238000013270 controlled release Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229920002988 biodegradable polymer Polymers 0.000 abstract 1
- 239000004621 biodegradable polymer Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229920000620 organic polymer Polymers 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108020001580 protein domains Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23136509P | 2009-08-05 | 2009-08-05 | |
| PCT/EP2010/061436 WO2011015634A2 (fr) | 2009-08-05 | 2010-08-05 | Formulations à libération contrôlée de mutéines de la lipocaline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00407A true IN2012DN00407A (fr) | 2015-08-21 |
Family
ID=43531164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN407DEN2012 IN2012DN00407A (fr) | 2009-08-05 | 2010-08-05 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120201873A1 (fr) |
| EP (2) | EP2550958B1 (fr) |
| JP (2) | JP2013501033A (fr) |
| KR (1) | KR20120099371A (fr) |
| CN (2) | CN102612362A (fr) |
| AU (2) | AU2010280688A1 (fr) |
| BR (1) | BR112012002709A2 (fr) |
| CA (1) | CA2770149A1 (fr) |
| IN (1) | IN2012DN00407A (fr) |
| RU (1) | RU2012107812A (fr) |
| WO (1) | WO2011015634A2 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| WO2012109363A2 (fr) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Vecteurs géniques pénétrant le mucus |
| US10064915B2 (en) | 2011-02-28 | 2018-09-04 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| US9701732B2 (en) | 2011-02-28 | 2017-07-11 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| EP2682406B1 (fr) * | 2011-02-28 | 2018-05-09 | Korea University Research and Business Foundation | Protéine de fusion comprenant de l'albumine et une protéine liant le rétinol |
| KR102038677B1 (ko) * | 2011-06-14 | 2019-10-30 | 입센 파마 에스.에이.에스 | 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물 |
| WO2013068590A1 (fr) * | 2011-11-11 | 2013-05-16 | Pieris Ag | Mutéines de lipocaline utilisées comme antagonistes du vegf destinées à être utilisées pour traiter des maladies provoquées ou favorisées par une vascularisation accrue |
| AP2014007792A0 (en) * | 2012-01-09 | 2014-07-31 | Pieris Ag | Methods for preventing, treating or diagnosing disorders |
| EP2809344B1 (fr) | 2012-02-02 | 2016-08-24 | ESBATech - a Novartis Company LLC | Formulation contenant des anticorps à libération prolongée pour l'application oculaire |
| CA2867203C (fr) | 2012-03-16 | 2016-09-20 | The Johns Hopkins University | Conjugues copolymere multi-blocs non lineaire-medicament pour l'administration de principes actifs |
| US8962577B2 (en) | 2012-03-16 | 2015-02-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| US9533068B2 (en) * | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CN103394094B (zh) * | 2013-07-16 | 2015-05-13 | 天津大学 | 基于牛血清白蛋白-聚己内酯的高分子脂质体及其制备方法 |
| CN103360609B (zh) * | 2013-07-16 | 2015-08-19 | 天津大学 | 一种双亲性的蛋白质-高分子键合体及其制备方法 |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US20160151511A1 (en) | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
| JP6846351B2 (ja) | 2015-01-27 | 2021-03-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤 |
| RU2727165C2 (ru) | 2015-05-04 | 2020-07-21 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| CA3014406A1 (fr) * | 2016-02-16 | 2017-08-24 | Strongbridge Biopharma plc | Veldoreotide de faible solubilite dans des conditions physiologiques destine a etre utilise dans le traitement d'une acromegalie, d'un cancer associe a une acromegalie, de tumeurs exprimant le sst-r5, du diabete de type 2, d'une hyperglycemie, et de tumeurs associees aux hormones |
| WO2020210805A1 (fr) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticules pour l'administration de médicaments au cerveau |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| WO1997004747A1 (fr) | 1995-07-27 | 1997-02-13 | Dunn James M | Systemes d'administration de medicaments pour medicaments macromoleculaires |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (fr) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Complexes d'amidon hydroxyethyles d'hemoglobine |
| JP3839667B2 (ja) | 1998-06-08 | 2006-11-01 | エフ．ホフマン−ラ ロシュ アーゲー | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| MXPA02003540A (es) | 1999-10-08 | 2003-09-12 | Nektar Therapeutics Al Corp | Derivados de poli(etilenglicol) heterobifuncionales y los metodos para su preparacion. |
| EP2316490A3 (fr) | 2000-10-31 | 2012-02-01 | PR Pharmaceuticals, Inc. | Methodes et compositions pour améliorer l'administration de molécules bioactives |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (fr) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteines de la lipocaline neutrophile humaine associee a la gelatinase et de proteines apparentees |
| US7118915B2 (en) | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| US9040664B2 (en) | 2003-04-11 | 2015-05-26 | Antriabio, Inc. | Materials and methods for preparing protein-polymer conjugates |
| AU2004259208B2 (en) * | 2003-07-15 | 2011-04-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
| AU2004259209A1 (en) * | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (fr) * | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteines de la lipocaline lacrymale |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| EP1996613B1 (fr) * | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteines de la lipocaline lacrymale presentant une affinite avec le corecepteur cd4 des lymphocytes t |
| DE602007009995D1 (de) | 2006-08-01 | 2010-12-02 | Pieris Ag | Muteine von tearlipocalin und verfahren zu deren gewinnung |
| US8178483B2 (en) * | 2007-03-30 | 2012-05-15 | Colgate-Palmolive Company | Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same |
| EP2142293A2 (fr) * | 2007-04-26 | 2010-01-13 | Basf Se | Procédé enzymatique de fabrication de microcapsules |
| EP2170287B1 (fr) * | 2007-07-26 | 2013-11-06 | Aqtis IP BV | Microparticules comportant un pcl et utilisations associées |
| SG2013054218A (en) * | 2008-01-15 | 2014-10-30 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| EP2245054B1 (fr) * | 2008-01-30 | 2018-11-28 | Pieris Pharmaceuticals GmbH | Mutéines de lipocaline de larmes ayant une affinité pour le récepteur tyrosine kinase c-met humain et procédés d'obtention de celles-ci |
| US20090274623A1 (en) * | 2008-01-30 | 2009-11-05 | General Electric Company | In vivo imaging agents for met receptor tyrosine kinase |
-
2010
- 2010-08-05 BR BR112012002709-3A patent/BR112012002709A2/pt not_active IP Right Cessation
- 2010-08-05 IN IN407DEN2012 patent/IN2012DN00407A/en unknown
- 2010-08-05 US US13/388,788 patent/US20120201873A1/en not_active Abandoned
- 2010-08-05 RU RU2012107812/15A patent/RU2012107812A/ru not_active Application Discontinuation
- 2010-08-05 CN CN2010800348503A patent/CN102612362A/zh active Pending
- 2010-08-05 CA CA2770149A patent/CA2770149A1/fr not_active Abandoned
- 2010-08-05 AU AU2010280688A patent/AU2010280688A1/en not_active Abandoned
- 2010-08-05 WO PCT/EP2010/061436 patent/WO2011015634A2/fr not_active Ceased
- 2010-08-05 EP EP12177932.6A patent/EP2550958B1/fr not_active Not-in-force
- 2010-08-05 CN CN201610084958.2A patent/CN106139123A/zh active Pending
- 2010-08-05 EP EP10747840A patent/EP2461800A2/fr not_active Withdrawn
- 2010-08-05 KR KR1020127005597A patent/KR20120099371A/ko not_active Ceased
- 2010-08-05 JP JP2012523344A patent/JP2013501033A/ja active Pending
-
2012
- 2012-08-08 JP JP2012176112A patent/JP5774557B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-07 AU AU2016204715A patent/AU2016204715A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2461800A2 (fr) | 2012-06-13 |
| EP2550958B1 (fr) | 2018-10-10 |
| US20120201873A1 (en) | 2012-08-09 |
| WO2011015634A2 (fr) | 2011-02-10 |
| JP2012255007A (ja) | 2012-12-27 |
| JP5774557B2 (ja) | 2015-09-09 |
| AU2010280688A1 (en) | 2012-02-23 |
| CA2770149A1 (fr) | 2011-02-10 |
| JP2013501033A (ja) | 2013-01-10 |
| CN106139123A (zh) | 2016-11-23 |
| AU2016204715A1 (en) | 2016-07-28 |
| RU2012107812A (ru) | 2013-09-10 |
| KR20120099371A (ko) | 2012-09-10 |
| WO2011015634A3 (fr) | 2011-04-14 |
| CN102612362A (zh) | 2012-07-25 |
| EP2550958A1 (fr) | 2013-01-30 |
| BR112012002709A2 (pt) | 2019-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011015634A3 (fr) | Formulations à libération contrôlée de mutéines de la lipocaline | |
| Illum | Nasal drug delivery—Recent developments and future prospects | |
| Guan et al. | N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy | |
| NZ600039A (en) | Biocompatible biodegradable fumagillin analog conjugates | |
| UA91512C2 (ru) | Коньюгати олигомеров инсулина, их композиция (варианты) и применение | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| Wang et al. | Ultrashort peptides and hyaluronic acid-based injectable composite hydrogels for sustained drug release and chronic diabetic wound healing | |
| US20160008477A1 (en) | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration | |
| GB0814302D0 (en) | Compounds and methods | |
| SG10201400685SA (en) | Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia | |
| EP2810661A3 (fr) | Conjugués peptidiques/polyéthylèneglycoles à liaison disulfure pour la transfection d'acides nucléiques | |
| MX368966B (es) | Conjugados de proteina-polimero-farmaco. | |
| EP4327888A3 (fr) | Formulations orales d'analogues de cytidine et leurs procédés d'utilisation | |
| WO2011094337A8 (fr) | Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité | |
| EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| UA104634C2 (xx) | Пегильована l-аспарагіназа $пегилированная l-аспарагиназа | |
| WO2012054500A3 (fr) | Compositions pour l'administration de médicaments | |
| WO2007100902A3 (fr) | Conjugués de polymères contenant de l'acryloyloxyéthylphosphorylcholine et leur préparation | |
| EP3895699A3 (fr) | Compositions pharmaceutiques contenant de l'oxyhroxyde de fer | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| SG194175A1 (en) | Polymer conjugated prostaglandin analogues | |
| EP2949344A3 (fr) | Utilisation d'enzymes intracellulaires pour libérer des produits bioactifs liés par covalence | |
| WO2013036309A3 (fr) | Formulation à libération prolongée pour administration de protéines à l'œil, et leurs procédés de préparation | |
| MX2009012782A (es) | Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados. | |
| TW201129396A (en) | Topical formulation |